Grey Matters Health’s planned NovaScan clinic in Florida will use the CareMiBrain dedicated PET system to expand access to amyloid imaging, while testing whether specialist neuroimaging can become a scalable outpatient service.
Find out how Hyperfine’s PRIME study could reshape emergency brain imaging with faster bedside portable MRI access.
Alzamend Neuro, the Nasdaq-listed clinical-stage biopharmaceutical company, has initiated a Phase II clinical trial of AL001, its ionic cocrystal lithium formulation, in patients diagnosed with bipolar disorder type 1, conducting the study at Massachusetts General Hospital in collaboration with Harvard Medical School investigators. The trial employs a crossover design in which participants receive both AL001